<?xml version="1.0" encoding="UTF-8"?>
<resource xmlns="http://datacite.org/schema/kernel-4" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.18453/rosdok_id00003037</identifier>
  <creators>
    <creator>
      <creatorName nameType="Personal">Shang, Yuru</creatorName>
      <givenName>Yuru</givenName>
      <familyName>Shang</familyName>
      <nameIdentifier nameIdentifierScheme="GND" schemeURI="http://d-nb.info/gnd/">http://d-nb.info/gnd/1234676052</nameIdentifier>
    </creator>
  </creators>
  <titles>
    <title>Immunoglobulin G mediates chemoresistance to oxaliplatin in colon cancer cells by inhibiting the ERK signal transduction pathway</title>
  </titles>
  <publisher>Universität Rostock</publisher>
  <publicationYear>2021</publicationYear>
  <resourceType resourceTypeGeneral="Text" />
  <subjects>
    <subject xml:lang="en" schemeURI="http://dewey.info/" subjectScheme="dewey">570 Life science</subject>
    <subject xml:lang="en" schemeURI="http://dewey.info/" subjectScheme="dewey">610 Medical sciences Medicine</subject>
  </subjects>
  <dates>
    <date dateType="Created">2021</date>
  </dates>
  <language>en</language>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="PURL">http://purl.uni-rostock.de/rosdok/id00003037</alternateIdentifier>
    <alternateIdentifier alternateIdentifierType="URN">urn:nbn:de:gbv:28-rosdok_id00003037-4</alternateIdentifier>
  </alternateIdentifiers>
  <descriptions>
    <description descriptionType="Abstract">The aim of this study was to investigate the effect of therapeutically used immunoglobulin G (IgG) on colon cancer in the presence of oxaliplatin. We observed that IgG failed to significantly influence tumor cell viability and tumor growth; however, it significantly inhibited the cytotoxic activity of oxaliplatin in vitro. In addition, we observed that oxaliplatin-induced the activation of ERK; however, IgG inhibits ERK activity. This implies that the application of therapeutical IgG to treating patients, which are receiving oxaliplatin, might have harmful side effects.</description>
  </descriptions>
</resource>
